New FDA Approvals for Lung Cancer, Myeloma

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

Experts weigh in on the practical applications of PSMA PET imaging

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Ashley Chan

Exploring Burnout Causes and Management in Oncologic Practice

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Eric P. Winer, MD

June 2nd 2025

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Ashling Wahner

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Roman Fabbricatore

JNJ-79635322 Shows Safety/Favorable Responses in R/R Multiple Myeloma

The addition of olanzapine to antiemetics might alleviate insomnia, appetite loss, anxiety, and depression in those receiving concurrent chemoradiation.

Related Content

Dylann Cohn-Emery

June 6th 2025

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

The 1-year progression-free survival rate for patients in the BCMA/GPRC5D naïve RP2D group was 95.0% and across all dose levels it was 74.1%.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

Experts weigh in on the practical applications of PSMA PET imaging

Ashley Chan

Exploring Burnout Causes and Management in Oncologic Practice

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Eric P. Winer, MD

June 2nd 2025

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Ashling Wahner

Olanzapine May Prevent Radiation-Induced Nausea and Vomiting

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.

Roman Fabbricatore